Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02522715 · ClinicalTrials.gov registry record · Phase 1
Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer
A Phase 1 study of Castration-Resistant Prostate Carcinoma and Metastatic Prostate Carcinoma, sponsored by OHSU Knight Cancer Institute.
- Active
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
- 3
- Study locations
NCT02522715 is a Phase 1 study of Castration-Resistant Prostate Carcinoma and Metastatic Prostate Carcinoma that is active but no longer recruiting, run by OHSU Knight Cancer Institute. The registered enrollment target is 37 participants, below the 77-participant average among 43 other Castration-Resistant Prostate Carcinoma trials with a reported enrollment target (52% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT02522715, a Phase 1 study of Castration-Resistant Prostate Carcinoma and Metastatic Prostate Carcinoma, is active but no longer recruiting, sponsored by OHSU Knight Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
- 3
- Study locations
Study Summary
This phase I/II trial studies the side effects and best dose of cabazitaxel when given together with enzalutamide in treating patients with prostate cancer that has spread to other places in the body (metastatic) and has not responded to treatment with hormones or no longer responds to treatment with hormones (hormone-resistant). Drugs used in chemotherapy, such as cabazitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Androgen can cause the growth of prostate cancer cells. Hormone therapy using enzalutamide may fight prostate cancer by blocking the use of androgen by the tumor cells. Giving cabazitaxel together with enzalutamide may work better in treating metastatic, hormone-resistant prostate cancer.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Prednisone
- DRUG Enzalutamide
- DRUG Cabazitaxel
- OTHER Pharmacological Study
Study Locations (3)
Oregon
- OHSU Knight Cancer Institute - Portland
- Portland VA Medical Center - Portland
Washington
- Seattle Cancer Care Alliance - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2015-08-13 |
| Est. Completion | 2027-01-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02522715
The ClinicalTrials.gov registry entry for NCT02522715 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 77-participant average among 43 other Castration-Resistant Prostate Carcinoma trials with a reported enrollment target (52% lower). The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Castration-Resistant Prostate Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02522715 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Oregon, Washington.
Frequently Asked Questions
What is clinical trial NCT02522715 about?
NCT02522715 is a clinical study titled "Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer". This phase I/II trial studies the side effects and best dose of cabazitaxel when given together with enzalutamide in treating patients with prostate cancer that has spread to other places in the body (metastatic) and has not responded to treatment with hormones or no longer responds to treatment wit...
What is the current status of trial NCT02522715?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2015-08-13. Estimated completion is 2027-01-01.
What conditions does trial NCT02522715 study?
This clinical trial studies the following conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7.
What interventions are being tested in trial NCT02522715?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Prednisone (DRUG), Enzalutamide (DRUG), Cabazitaxel (DRUG), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT02522715?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02522715 being conducted?
This trial has 3 study locations across Oregon, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Castration-Resistant Prostate Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 1
-
Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 1
-
Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy
RECRUITING · Phase 1
-
Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
RECRUITING · Phase 1
-
Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer
RECRUITING · Phase 1
-
Imaging of Solid Tumors Using 18F-TRX
RECRUITING · Phase 1
Explore more on PlainTrial
Castration-Resistant Prostate Carcinoma
All registered trials for this condition
Metastatic Prostate Carcinoma
All registered trials for this condition
Oregon
All trials with a study site in Oregon
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.